Navigation Links
Drug May Help Against Inflammatory Breast Cancer
Date:4/27/2009

Study shows those who respond to lapatinib survive longer,,,,

MONDAY, April 27 (HealthDay News) -- The drug lapatinib could be used to treat aggressive inflammatory breast cancer, suggest the findings of a phase 2 study.

Inflammatory breast cancer accounts for up to 6 percent of all invasive breast tumors in the United States and western Europe, according to the researchers. Symptoms include rapid onset of swelling, redness of breast skin, a pitted appearance caused by fluid under the skin of more than two-thirds of the breast, tenderness, hardening and warming of the breast.

For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in other, less aggressive breast cancers.

The study included 126 women who took 1,500 milligrams of lapatinib once a day. None of them showed a full response to the drug, but 39 percent had a partial response, the researchers reported. Median progression-free survival was 15 weeks and, at 6 months, 22 percent of the women were still progression-free.

When the researchers divided the participants into four groups, they found that median overall survival was:

  • 18.4 months for those who responded to lapatinib after previous treatment with trastuzumab
  • 14 months for those who responded to lapatinib and had no previous trastuzumab treatment
  • 8.4 months for those unresponsive to lapatinib who had previously taken trastuzumab
  • 8.2 months for those unresponsive to lapatinib who had not previously taken trastuzumab.

The study found that 92 percent of the women had at least one adverse event, including shortness of breath and fluid around the lungs. Five participants died from adverse events that were possibly treatment related, said the Israeli and U.K. researchers.

"Patients who responded to treatment with lapatinib had a longer median overall survival than did those patients who did not respond, irrespective of previous exposure to trastuzumab," the researchers wrote. "Patients exposed to previous trastuzumab treatment who experienced a response to lapatinib had the longest median overall survival. This finding confirms the clinical benefit of targeted therapy in these patients."

"Lapatinib monotherapy is potentially clinically effective in heavily pretreated patients with inflammatory breast cancer with HER2+ tumors," they said. "The objective response rate noted ... coupled with the median duration of response and median overall survival supports a role for lapatinib in these patients."

The study appears online and in the June print issue of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about inflammatory breast cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, April 26, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Despite overeating, morbidly obese mice gain protection against diabetes
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
8. $52.5 Million Settlement Against Sepracor Inc. Approved
9. The fight against colorectal cancer
10. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
11. Breastfeeding does not protect against asthma, allergies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Help Against Inflammatory Breast Cancer
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business ... Awards . The annual awards, now in their 12th year, are among the most ... winners. , In 2016, the awards were retooled to recognize achievements in both large ...
(Date:3/24/2017)... Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... new clinic which can be found at 9618 Huebner Road. The clinic is the ... PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter ... demand for the product – with nearly 2,000 consumers (and counting) already backing ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: